TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE D-

NCT07378644: Study to Evaluate the Pharmacodynamics, Safety and Efficacy of SKY-0515 in Participants With Huntington's Disease

Sponsor: Skyhawk Therapeutics, Inc. · Phase: PHASE2/PHASE3 · Area: RARE_ORPHAN · Target Enrollment: 400 pts

Competing Trials Overlap

14 Active Trials

Excess Burn Exposure

$7,728,090

Rescue Site Savings

+$5,089,230

Unlock Full NCT07378644 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07378644 Rescue Dossier →